Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.46 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5362392 | 0.89 | FDPS (0.53) | FDPSSMN1; SMN2HIF1APTPN1GGPS1 | |
| SCHEMBL11296838 | 0.86 | FDPS (0.50) | FDPSSMN1; SMN2HIF1APTPN1GGPS1 | |
| SCHEMBL8528147 | 0.82 | FDPS (0.46) | FDPSSMN1; SMN2HIF1APTPN1GGPS1 | |
| SCHEMBL6397780 | 0.79 | PTPN1 (0.60) | FDPSPTPN1PTPRCTSHR | |
| SCHEMBL417167 | 0.78 | MMP8 (0.58) | FDPSSMN1; SMN2PTPN1PTPRC | |
| SCHEMBL11341651 | 0.77 | FDPS (0.56) | FDPSSMN1; SMN2HIF1APTPN1GGPS1 | |
| SCHEMBL7264380 | 0.77 | FDPS (0.67) | FDPSSMN1; SMN2HIF1APTPN1GGPS1 | |
| SCHEMBL3075655 | 0.77 | FDPS (0.67) | FDPSSMN1; SMN2HIF1APTPN1GGPS1 | |
| SCHEMBL29009442 | 0.76 | MMP8 (0.56) | FDPSSMN1; SMN2PTPN1PTPRC | |
| SCHEMBL11683760 | 0.76 | PTPN1 (0.48) | FDPSPTPN1PTPRCCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4204441-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022046739-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-10689430-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
| EP-3463413-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme Corp. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017205309-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20120022024-A1 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010123599-A9 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-02-17 | — | — | WO | disclosed |
| WO-2010123599-A2 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-10-28 | — | — | WO | disclosed |
| US-6107284-A | Water-soluble derivatives of epipodophyllotoxin, process for their preparation, their use as medicinal products and their intended use in anti-cancer treatments | PIERRE FABRE MEDICAMENT (FR) | 2000-08-22 | — | — | US | disclosed |
| US-4151302-A | Araliphatic dihalogen compounds composition and method of use | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1979-04-24 | — | — | US | disclosed |
| US-4057647-A | Araliphatic dihalogen compounds and process for their preparation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022024-A1 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | CUTA, MMP8, CLPP | FDPS 2463/4885SMN1; SMN2 4479/4885HIF1A 1267/4885 |
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | FDPS 4071/4885SMN1; SMN2 3416/4885HIF1A 3716/4885 |
| US-10689430-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | FDPS 4071/4885SMN1; SMN2 3416/4885HIF1A 3716/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | FDPS 4071/4885SMN1; SMN2 3416/4885HIF1A 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.